Harmony Biosciences Files 8-K

TL;DR

Harmony Biosciences filed an 8-K on June 5th, updating corporate info. All good.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on June 5, 2025, reporting on other events and financial statements. The filing details the company's principal executive offices located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462, with a business phone number of (484) 539-9800. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing provides an official update on Harmony Biosciences' corporate information and regulatory filings, which is important for investors and stakeholders to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain information that suggests a significant change in risk for the company.

Key Players & Entities

• Harmony Biosciences Holdings, Inc. (company) — Registrant
• June 5, 2025 (date) — Date of report
• 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462 (location) — Principal executive offices
• 001-39450 (other) — Commission File Number
• 82-2279923 (other) — IRS Employer Identification No.

FAQ

From the Filing

0001558370-25-008415.txt : 20250605 0001558370-25-008415.hdr.sgml : 20250605 20250605083013 ACCESSION NUMBER: 0001558370-25-008415 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250605 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250605 DATE AS OF CHANGE: 20250605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 251025089 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20250605x8k.htm 8-K 0001802665 false 0001802665 2025-06-05 2025-06-05 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of report (Date of earliest event reported): June 5, 2025 HARMONY BIOSCIENCES HOLDINGS, INC . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) ​ 630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code) ( 484 ) 539-9800 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​      Trading      Name of each exchange Title of each class ​ Symbol(s) ​ on which registered Common Stock, $0.00001 par value per share ​ HRMY ​ The Nasdaq Global Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 8.01. Other Events. ​ On June 5, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing a settlement agreement with Lupin Limited (“Lupin”), resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will be dismissed, and Lupin will receive a license to launch its generic product no earlier t